Percutaneous Ultrasonography-Guided Permanent Iodine-125 Implantation as Salvage Therapy for Recurrent Head and Neck Carcimonas
Twenty-nine (29) patients with recurrent head and neck carcinomas underwent 125I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of 125I seed implantation were assessed.The postplan evaluation showed that the actuarial D90 of 125I seeds ranged from 90 to 160 Gy (median, 130 Gy).The activity of each 125I seed ranged from 0.35 to 0.8 mCi (median, 0.6mCi).The total number of sources implanted ranged from 3 to 61 (median, 22).The follow-up ranged from 3 to 40 months (median, 8 months).The1-, 2-, and 3-year local control rates were 53.1%, 34.8%, and 17.4%, respectively, with a median local control of 16months (95% confdence interval, 5.8-26.1).The 1-, 2-, and 3-year survival rates were 54.1%, 27.5%, and 27.5%,respectively (median, 13 months; 95% confidence interval, 6.0-19.9).Of the 25 patients, 5 (17.2%) died of local recurrence and 7 (24.1%) died of metastases; 2 patients showed recurrences at 3 and 8 months after seed implantation and subsequently died of pneumonia.One (1) patient died of heart disease.One (1) developed ulceration with tumor progression.Blood vessel damage and neuropathy were not observed.Percutaneous ultrasound-guided 125I seed implantation is a feasible, safe salvage for patients with recurrent carcinomas of the head and neck.
head and neck 125I seed implantation outcome recurrent carcinoma ultrasonography
Ping Jiang Yuliang Jiang Jun-jie Wang Na Meng Weiqiang Ran Ang Qu Ruijie Yang
Radiation Oncology,Peking University 3rd Hospital, Beijing, P.R.China Ultrasound, Peking University 3rd Hospital, Beijing, P.R.China
国内会议
北京大学医学部放射肿瘤学系成立大会暨北京大学第二届国际放射肿瘤学术论坛
北京
英文
14-18
2012-05-23（万方平台首次上网日期，不代表论文的发表时间）